we'll see how this graphic holds up as new data emerges..for instance svr estimates for 2009+ range may be low, there's a chance combination protease-polymerase combination may be investigated (and become standard) sooner than expected (just a hunch), and if ana-975 gets back to clinic and progresses efficiently (big ifs), we might see an all oral regimen prior to 2015 (dew - i know you don't think much of ana-975, but it just might be the non-interferon answer to augmenting t-cell immunity..and btw i own no shares, just an interesting product given its unique moa for hep c)
Market Data 
Markets 
AI
